Skip to main content

Table 1 Overview of the intended chemotherapy protocol (* patients treated 2009–2013, ** patients treated 2005–2008, i.v. = intravenous, MTX = methotrexate, AraC = cytarabine, i.th. = intrathecal)

From: HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis

 

Day 0

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Cycle 1–3 (1 cycle = 2 weeks)

- Rituximab 500 mg/m2 i.v.*

x

      

- MTX 3000–5000 mg/m2 i.v.

 

x

     

- Ifosfamide 800 mg/m2 i.v.

  

x

x

x

  

- Liposomal AraC 50 mg i.th.**

  

x

    

Cycle 4 + 6 (1 cycle = 3 weeks)

- Cytarabine 3000 mg/m2 i.v

 

x

x

    

- Liposomal AraC 50 mg i.th.**

   

x

   

- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)*

   

x

x

x

 

- AraC 10 mg intraventricular (patients < 65 ys)*

      

x

Cycle 5 (1 cycle = 2 weeks)

- MTX 3000–5000 mg/m2 i.v.

 

x

     

- Ifosfamide i.v. 800 mg/m2 i.v.

  

x

x

x

 

- Liposomal AraC 50 mg i.th.**

  

x

   

- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)*

  

x

x

x

 

- AraC10 mg intraventricular (patients < 65 ys)*

     

x

Cycle 5 was repeated for patients < 65 ys